Voiant leverages the most advanced technology to deliver operational excellence and consistent execution. Learn more about our clinical trial imaging CRO.
Location: United States, Ohio, Minerva Park
Employees: 201-500
Investors 1
| Date | Name | Website |
| 04.11.2023 | DFW Capita... | dfwcapital... |
Mentions in press and media 9
| Date | Title | Description |
| 06.11.2025 | Voiant Publishes Breakthrough Research on Deep Learning for Geographic Atrophy Quantification in Diagnostics Journal | Voiant announces the publication of a peer-reviewed study in Diagnostics demonstrating a deep learning-based method for automated geographic atrophy (GA) quantification in SD-OCT imaging. The study validates Orion, Voiant's cloud-based read... |
| 08.07.2025 | Voiant Expands Regulatory Capabilities with the Completion of a Successful FDA Remote Regulatory Assessment (RRA) | Laura Guzman, VP of Quality Assurance & Regulatory Compliance, Voiant Voiant successfully completed its first FDA Remote Regulatory Assessment (RRA) with no observations or concerns, demonstrating its strong compliance, innovative infra... |
| 29.05.2025 | Voiant Launches Voiant Hub 2.0 at ASCO: Setting a New Standard in Clinical Trial Imaging | Voiant Hub 2.0 is the newest version of Voiant trusted platform that is set to transform the industry. At the core of this innovation is Voiant ReadReady™, a proprietary image flow optimization process developed by Voiant AI Lab. ReadReady™... |
| 17.04.2025 | Voiant Acquires Voxeleron to Expand with AI Technology | April 15, 2025 – Voiant, a leader in clinical trial imaging solutions, today is announcing the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant advancement... |
| 15.04.2025 | Voiant Acquires Voxeleron to expand ophthalmic clinical research with AI Technology | Voiant Acquires Voxeleron Voiant, a leader in clinical trial imaging solutions, today is announcing the acquisition of Voxeleron, a pioneering company in AI-driven ophthalmic image analysis. This strategic acquisition marks a significant ad... |
| 18.02.2025 | Voiant Delivers Primary Endpoints in Two New Drug Approvals for Colorectal Cancer and Glioma Following Successful FDA Inspections | CRC & Glioma Voiant, a leader in AI-driven clinical trial imaging, supported the FDA approvals of two cancer treatments for colorectal cancer and glioma by delivering key imaging endpoints for pivotal trials. Following successful FDA in... |
| 03.06.2024 | Voiant Boosts Ophthalmology Imaging Services, Doubling Reader Capacity | Voiant Ophthalmology (formerly known as D.A.R.C.) Voiant, a leader in clinical trial imaging solutions, today announced significant enhancements to its ophthalmology imaging services. These strategic advancements, including focused investme... |
| 24.04.2024 | Voiant and Thirona announce commercial partnership for full scope services in imaging-based clinical trials for pulmonary diseases | Voiant & Thirona Announce Commercial Partnership Voiant (USA) and Thirona (The Netherlands) are pleased to announce they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmona... |
| 02.04.2024 | Voiant's Commitment to Quality Affirmed by FDA Inspection with No Findings Raised | Laura Guzman, VP of QA and Regulatory Compliance, Voiant Voiant, a leader in clinical trial imaging solutions, is proud to announce the successful completion of an inspection conducted by the U.S. Food and Drug Administration (FDA). WALTHAM... |